Klinische Studie

BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

NCT: NCT02876042 · COMPLETED

NCT-IDNCT02876042

Medizinische Daten: StatusCOMPLETED

Startdatum2017-03-23

Abschluss2025-11-03

SponsorCVRx, Inc. (INDUSTRY)

First posted2016-08-23

Last updated2026-09-11

Kurzzusammenfassung

The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (HFpEF).

Offizielle Quelle

Auf ClinicalTrials.gov ansehen →

Daten aus der ClinicalTrials.gov-API. Den aktuellsten Status finden Sie im offiziellen Eintrag.